Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

By sjmartinez • January 18, 2024

Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine T; ProDERM investigators. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2. PMID: 38233885.

Tags: Dermatomyositis, Intravenous immunoglobulin, Myositis, Publications, Rheumatology, safety, Tolerability

Sexual health outcomes following gender affirming metoidioplasty: a systematic review

Goldstein B, Uloko M, Okamuro K, Moore M, Peters BR, Blumenthal J, Marinkovic M, Anger J. Sexual health outcomes following gender affirming metoidioplasty: a systematic[...]

Bidirectional risk between autoimmune blistering diseases and posttraumatic stress disorder

Kasperkiewicz M, Ludwig RJ, Curman P. Bidirectional risk between autoimmune blistering diseases and posttraumatic stress disorder. J Eur Acad Dermatol Venereol. 2025 Oct 17. doi:[...]

Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer

Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall M, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter[...]